(Q38129725)

29 August 2017

title

Opportunities and hurdles in the treatment of BRCA1-related breast cancer (English)

1 reference

29 August 2017

1 reference

R Drost

1

1 reference

29 August 2017

J Jonkers

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

19 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

33

1 reference

29 August 2017

issue

29

1 reference

29 August 2017

page(s)

3753-3763

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2013.329

29 August 2017

exact match

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Global trends in breast cancer incidence and mortality 1973-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Gene expression profiling in breast cancer: classification, prognostication, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Inherited mutations in breast cancer genes--risk and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Clinical management of hereditary breast cancer syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Prognosis of BRCA-associated breast cancer: a summary of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 and BRCA2: different roles in a common pathway of genome protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

THE GENETICS OF BREAST CANCER SUSCEPTIBILITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cancer Incidence in BRCA1 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cancer risks in BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 methylation: a significant role in tumour development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Negative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Localization of BRCA1 and a splice variant identifies the nuclear localization signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

An amino-terminal motif functions as a second nuclear export sequence in BRCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 and its toolbox for the maintenance of genome integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Identification of a RING protein that can interact in vivo with the BRCA1 gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The BRCA1 ubiquitin ligase and homologous recombination repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

PALB2 links BRCA1 and BRCA2 in the DNA-damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Association of BRCA1 with Rad51 in mitotic and meiotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Unraveling the mechanism of BRCA2 in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Purified human BRCA2 stimulates RAD51-mediated recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Links between genome integrity and BRCA1 tumor suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 is a cell cycle-regulated nuclear phosphoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cancer susceptibility and the functions of BRCA1 and BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 is associated with the centrosome during mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Roles of BRCA1 in centrosome duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Evidence for a transcriptional activation function of BRCA1 C-terminal region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 is required for postreplication repair after UV-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Improved survival in women with BRCA-associated ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

DNA interstrand crosslink repair and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Current and future potential roles of the platinum drugs in the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Repair of cisplatin--DNA adducts by the mammalian excision nuclease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

PARP inhibitors stumble in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Molecular mechanisms of resistance and toxicity associated with platinating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 tumor suppressor network: focusing on its tail

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

The potential role and application of PARP inhibitors in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 phosphorylation: biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Negative Regulation of AKT Activation by BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Targeting the Akt/mTOR pathway in Brca1-deficient cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Proteasome function is required for DNA damage response and fanconi anemia pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 16 years later: DNA damage-induced BRCA1 shuttling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Transcriptional activation by BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Triple negative tumours: a critical review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

p53 mutations in BRCA1-associated familial breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.329

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.329

1 reference

Dimensions Publication ID

29 August 2017

1051479849

0 references

1 reference